Trail, a tumor necrosis factor-related apoptosis-inducing ligand, is a novel potent endogenous activator of the cell death pathway through the activation of cell surface death receptors Trail-R1 and Trail-R2. Its role, like FasL in activation-induced cell death (AICD), has been demonstrated in immune system. However the mechanism of Trail induced apoptosis remains unclear. In this report, the recombinant Trail protein was expressed and purified. The apoptosis-inducing activity and the regulation mechanism of recombinant Trail on Jurkat T cells were explored in vitro. Trypan blue exclusion assay demonstrated that the recombinant Trail protein actively killed Jurkat T cells in a dose-dependent manner. Trail-induced apoptosis in Jurkat T cells were remarkably reduced by Bcl-2 over expression in Bcl-2 gene transfected cells. Treatment with PMA (phorbol 12-myristate 13-acetate), a PKC activator, suppressed Trail-induced apoptosis in Jurkat T cells. The inhibition of apoptosis by PMA was abolished by pretreatment with Bis, a PKC inhibitor. Taken together, it was suggested that Bcl-2 over-expression and PMA activated PKC actively down-regulated the Trail-mediated apoptosis in Jurkat T cell.
INTRODUCTION
Trail [1] (TNF-related apoptosis inducing ligand) is a recently described member of the TNF family. Like other members of the TNF ligand family, Trail could induce apoptosis of neoplastically transformed cells by activating cell surface death receptors Trail-R1 and Trail-R2 [2] .
Trail has been demonstrated to play an important role in homeostasis of immune system including eradication of the old lymphocyte [3] , activationinduced T cell death [4] , regulation of T cell expansion by B cells, and T cell-mediated cytotoxicity etc. T and B lymphocytes express surface Trail that participates in activation induced cell death (AICD). However, the regulation of Trail protein in immune cells has not been fully determined.
It is widely accepted that apoptosis is controlled by several genetic programs. In the past decade, studies have demonstrated that there are two major cell intrinsic pathways for regulating apoptosis: one is receptor-mediated pathway, for example FasFasL pathway, the other is mitochondria-mediated pathway, such as Bcl-2 family genes. The two pathways were directly linked by Bid, a proapoptotic member of Bcl-2 family [5] . Bcl-2 inhibits apoptosis induced by many signals such as ultra-violet radiation, anti-tumor drugs and deprivation of growth factor. We also find that Bcl-2 inhibits FasLinduced apoptosis in hepatoma BEL-7404 [6] . The effect of Bcl-2 on Trail-induced apoptosis remains controversial, for example Bcl-2 can block Trailinduced apoptosis in glioma LN-229 cells [7] but not in myeloma ARP-1 cells [8] . It seems that the Trail shows different effects on different cell types.Protein kinase C (PKC), a serine/threonine kinase that plays an essential role in the phosphorylation of proteins involved in signal transduction pathways, can inhibit FasL induced apoptosis in Jurkat T cells [9] , but whether it regulates the Trail-induced apoptosis remains to be investigated. The aim of this study is to investigate the regulation of Trail-induced apoptosis and examine whether the activation of PKC and over-expression of Bcl-2 affect Trail-induced apoptosis in Jurkat T cells. In the present work, we cloned and expressed recombinant Trail protein and confirmed that the recombinant Trail protein could induce apoptosis in Jurkat T cell. PMA inhibited Trailinduced apoptosis in Jurkat T cells, while the Bis, an inhibitor of PKC, abolished the inhibitory effect of PMA on the Trail-induced apoptosis. In addition, we also examined and found no effect of other immunoactivator including LPS, IL-2, PHA on Trail-induced apoptosis. Over-expression of Bcl-2 constructed by transfecting the Bcl-2 gene into Jurkat T cells could suppress Trail-induced apoptosis in Jurkat T cell. The results suggested that Bcl-2 over-expression and PKC activation inhibited Trail-induced apoptosis in Jurkat T cell.
MATERIALS AND METHODS

Chemicals
P h o r b o l 1 2 -m y r i s t a t e 1 3 -a c e t a t e ( P M A ) , B i s (bisindolylmaleimide I, HCl), PHA, IL-2, Diazobenzidine (DAB), G418 were purchased from Sigma Chemical Co. Anti-Bcl-2 antibody and HRP-conjugated second antibody were purchased from Santa Cruz Biotechnology Inc.
Cell culture
Jurkat T cells (human T lym phoma, CAS Cell Bank) were routinely cultured in RPMI 1640 medium (GibcoBRL) supplemented with 10% newborn bovine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin. The cells were maintained at 37 o C in a humidified atmosphere with 5% CO 2 . Cell viability was assessed by trypan blue exclusion. Expression and purification of Trail protem.
Expression and purification of Trail protein
Prokaryotic expressing plasmid pT7-6His-Trail was transformed into E.coli. BL21(DE3) and induced to express 6His-Trail fusion protein at 37 o C under 0.1 mM IPTG induction for 4 h. The cell culture was harvested and washed with sonication buffer for 3 times. Then the cells were resuspended in sonication buffer and incubated on ice for 30 min after adding 1 mg/ml lysozyme and PMSF. The cells were sonicated on ice and centrifuged at 12000 g for 30 min at 4 o C. The supernatant was collected and mixed with pre-equilibrated Ni + -NTA resin in sonication buffer for binding for 1 h at 4 o C. After washing the mixture for 3 times, the protein was eluted with elution buffer (0.3 M imidazole in sonication buffer). The eluate was collected, and imidazole was removed by dialysis in PBS. The precipitate was also collected and washed with washing buffer for three times. The purity of purified recombinant protein was inspected by PAGE electrophoresis and the concentration of purified recombinant protein was determined by Bradford method. Finally, the purified recombinant protein was stored at -20 o C in 100 μl fractions.
Transient transfection of Jurkat T cells with BCL-2 gene (using electroporation method)
The apparatus used in the experiment was Gene PulserTM (BIORAD). Jurkat T cells growing to exponential stage were pooled, rinsed twice with D-Hanks saline solution and suspended in D-Hanks at 0.5-1.0 10 7 cells/ml. Eukaryotic expressing Plasmid pcDNA3-Bcl-2 (Bcl-2 cDNA was inserted into vector pcDNA3 at EcoR I site) was added to cells culture at a final concentration of 30 μg/ml and incubated on ice for 10 min. Then cells were electroporated at 500V, 25μF and 100 and incubated on ice for another 10 min. Appropriate amount of cells were inoculated into RMPI1640 and developed in 37 o C, 5%CO 2 . The transfected Jurkat T cells were selected with 800 μg/ml G418 for 2 w.
Western blot analysis
The Bcl-2 protein expression was determined by western blot analysis. In brief, 10μg of total protein extracted from Jurkat T cells or transfected cells were separated by SDS-PAGE, transferred onto nitrocellulose membrane and probed with mouse anti-human Bcl-2 monoclonal antibody. Membrane was subsequently incubated with HRP-conjugated second antibody and finally developed with diaminobenzidine and H 2 O 2 .
Apoptosis assay
The induction of apoptosis of Jurkat T cells by treatment with purified recombinant Trail protein in different doses and times was assessed by examination of cellular morphological changes under light microscopy and nuclear division stained with propidium iodide (PI) by fluorescent microscope. In brief, the harvested cells were washed three times with D-Hanks and fixed in sodium citrate at 4 o C for 30 min. 500 μl staining solution (PI 50 μg/ml, RNase 10 μg/ml) was added to 10 6 cells and incubated at 4 o C for 15 min in dark before the microscope examination.
Effect of PKC activity on trail-induced apoptosis
The Jurkat T cells were pretreated with PMA (10 ng/ml), PHA (50 μg/ml), IL-2(10U/ml), LPS (100 ng/ml) for 12 h, followed by 100 ng/ml Trail protein treatment for additional 12 h. Cell viability was assessed by trypan blue exclusion. In PKC activity assay, before treatment with PMA the Jurkat T cells were incubated with Bis (0.15 μM) for 4 h. The apoptotic experiments were repeated at least three times.
RESULTS
Expression and purification of recombinant Trail protein
The Trail gene was cloned by RT-PCR and the sequence was confirmed by sequencing (data not shown). The recombinant Trail protein was ex-pressed in E.coli. BL21 (DE3) and purified with Ni + -NTA agarose column. The purified 21kDa recombinant Trail protein (shown in Fig 1) was used in the following experiments to detect its effect on apoptosis induction in Jurkat T cells.
Recombinant Trail protein induces apoptosis in Jurkat T cells
In order to investigate the biological activity of recombinant Trail protein on Jurkat T cells, various dosages of purified protein were added to treat the Jurkat T cells. In culture, the Jurkat T cells grew and proliferated into aggregated groups (Fig  2A) . After 4 h treatment with 100 ng/ml Trail protein, the cells began to appear the characteristics of apoptosis showing cell disaggregation, and cellular shrinkage (Fig 2B) . Furthermore the condensation of chromatin and breakdown of the nucleus into several smalls pieces were also seen (Fig 2C) . The occurrence of apoptosis was quantitated by Typan Blue assay. As shown in Tab 1, the Jurkat T cells were very sensitive to recombinant Trail protein treatment, resulting in an induction of apoptosis in a dose-dependent manner. Bcl-2 as an anti-apoptosis gene was initially isolated from a follicular lymphoma and has been shown to enhance the survival of a variety of cell types exposed to diverse cell death-inducing stimuli. To investigate the effect of Bcl-2 protein on Trailinduced apoptosis in Jurkat T cells, a reconstructed eukaryotic expressing vector pcDNA3-Bcl-2 was transfected into Jurkat T cells by electroporation. The cells were selected for 2 w with 800mg/ml G418. The results showed that the Jurkat T cells transfected with Bcl-2 expressing vector expressed 26 kDa Bcl-2 protein as showed in Western blot of Fig 3A in comparison with control parent Jurkat T cells and pcDNA3 plasmid transfected cells.
Over-expression of Bcl-2 delays Trail induced-
Bcl-2 over-expressing Jurkat T cells, parent Jurkat T cell and pcDNA3 transfected Jurkat T cells were treated with 100 ng/ml purified Trail protein for 12 h. The results showed that the Trail protein induced 83.2% of parent Jurkat T cells to undergo apoptosis, while the Bcl-2 protein overexpressed Jurkat T cells showed remarkable resistance to Trail-induced apoptosis, resulting in a reduction of apoptosis rate from 83.2% to 32.6% of the cells. There was no significant effect of pcDNA3 transfection on cells apoptosis induced by Trail ( Fig  3B) . These results indicated that over-expression of Bcl-2 obviously suppressed the apoptosis induced by Trail in Jurkat T cells.
PMA inhibits apoptosis induced by Trail in Jurkat T cell through activation of PKC
PMA is an effective activator of PKC, which participates in regulating apoptosis induced by many stimuli, for example FasL in Jurkat T cells. To investigate whether PMA had inhibitory effect on Trail-induced apoptosis, Jurkat T cells were pretreated with PMA (10 ng/ml) for 12 h followed by incubation with 100 ng/ml recombinant Trail for additional 12 h. As shown in Fig 4, PMA significantly protected Jurkat T cells from the Trailinduced apoptosis, reducing the apoptotic cells rate to 11.7%, in comparison with 82.4% apoptosis of control Jurkat T cells during incubation with same amount of Trail. In order to investigate whether the activation of PKC during the PMA pretreatment was the cause of protection in Jurkat T cells, Bis (0.15 μM), an inhibitor of PKC, was added for 4 h before the treatment of PMA (10 ng/ml) to inhibit the activity of PKC. The results in Fig 5 indi cated that Bis pretreatment obviously abolished the apoptosis-inhibiting effect of PMA, while Bis alone had no effect on Trail-treated Jurkat T cells. These results implied that the activation of PKC pathway might be responsible for the inhibition of apoptosis by PMA in the Trail-treated Jurkat T cells.
In addition, we examined the effect of other immunoactivator such as LPS, PHA and IL-2 on Trail-induced apoptosis. Jurkat T cells were pretreated with PHA (50 g/ml), IL-2 (10 U/ml) and LPS (100 ng/ml) for 12 h followed by incubation with 100 ng/ml recombinant Trail for additional 12 h. As shown in 
DISCUSSION
Lymphocyte death by apoptosis is an essential mechanism for maintaining homeostasis of immune system. The expression of cell surface receptors such as CD40, CD20, CD2, Fas, TNFR and Trail-Rs seems to be required in determining whether lymphocytes survive or undergo apoptosis [10] . Like FasL, Trail triggers apoptotic death by activating the cell surface death receptor Trail-R1 and Trail-R2 [2] . It is further comfirmed that Trail receptors Trail-R3 and Trail-R4 with truncated cytoplasmic region can protect the target cells from Trail-induced apoptosis.
Bcl-2 is a anti-apoptosis gene that can inhibit apoptosis induced by many stimuli, for example, irradiation, TNF-α, FasL and deprivation of growth factor. The effect of Bcl-2 on Trail-induced apoptosis are controversial [7] , [8] mainly depending on different cell types. In order to investigate the effect of Bcl-2 on Trail-induced apoptosis in Jurkat T cells, we inspected the endogenous Bcl-2 expression and found the expression level of Bcl-2 was low (Fig 2 lane 2) . We did find that Bcl-2 overexpression could suppress Trail-induced apoptosis in Jurkat T cells. These results suggested that the effect of Bcl-2 on Trail-induced apoptosis might depend on cell types and their properties. There are two subclasses of Bcl-2 family functioning as either anti-apoptosis regulators including Bcl-2, Bcl-XL pro-apoptotic proteins, for example, Bid, Bax etc. Bid existed in the cytosolic fraction of living cells as an inactive precursor. It was reported that Bid protein was activated by cleavage of precursor via activation of caspase 8 triggered by Trail in human B lymphoma BJAB cells and FasL in Jurkat T cells [11] , [12] . It has been demonstrated that FADD and caspase 8 participate in the apoptotic signal pathway [13] . Our results suggested that the Trail induced cell death in Jurkat T cells might depend on the Bid activation resulted from Trail treatment caused caspase 8 activities, because Bcl-2 over-expression protected the Jurkat T cells from Trail induced apoptosis by competitively heterodimerizing with Bid protein.
Bcl-2 gene expression not only suppresses Trailinduced apoptosis in Jurkat T cell but also inhibits FasL-induced apoptosis in hepatoma cells [6] . Previous reports have revealed that activation of PKC could inhibit FasL-induced apoptosis in Jurkat T cells [9] . It is interesting to see whether PKC might also participate in the regulation Trail-induced apoptosis. In this study, we found that PMA, a PKC activator, could inhibit Trail-induced apoptosis in Jurkat T cell and this inhibitory effect could be abolished by Bis, an inhibitor of PKC. Our results demonstrated that PMA inhibited Trail-induced apoptosis by activating PKC.
It was reported that the adjustment of Fas-mediated apoptosis by activation of PKC occurred at a site upstream of caspase-8 and caspase-3 [9] . It suggested that PKC may regulate the activities of these cysteine proteases through unknown molecules existing upstream of caspase 8 which play a center role in Trail-induced apoptosis, because caspase-8 inhibitor can inhibit Trail-induced apoptosis [14] . When PKC was activated it could inhibit many stimulus induced apoptosis in cells, such as UV in U937 cells [15] , TNF-α and FasL in human lymphoma cells [16] , [17] . Han [18] demonstrated that PKC took part in regulating the release of cytochrome C and Ro-31-8220 (an inhibitor of PKC) could induce apoptosis in HL-60 cells by the process of mitochondrial cytochrome C efflux and the activation of caspase-3. In this study, we found that PKC activation drived by PMA treatment on Jurkat T cells could inhibit Trail-induced apoptosis. The inhibitory effect of PMA might be due to expression of an unknown proteins existing upstream of caspase-8 that could inhibit the activation of caspase-8 or caspase-3.
Our results suggested that the level of Bcl-2 protein and activity of PKC affected the anti-tumor activity of Trail. Decrease of Bcl-2 expression and inhibition of PKC activity might enhance the anti-tumor activity of Trail. It is helpful for design of a new tumor therapy stratgy.
